• Doxorubicin Hydrochloride: Assay Workflows

  2026-09-17

  Build reproducible cancer chemotherapy research workflows with Doxorubicin hydrochloride, from dose–response and apoptosis assay design to DNA-damage profiling. The same compound also supports a translational cardiotoxicity model when cardiac function, oxidative stress, and ferroptosis-linked endpoints are measured together.

• Dual-Action Inhibitors Reshape p38α Dephosphorylation

  2026-09-17

  A 2024 bioRxiv study shows that selected kinase inhibitors can do more than block p38α activity: they can also increase WIP1-mediated dephosphorylation of the activation-loop phosphothreonine. Structural data explain this effect by revealing inhibitor-stabilized activation-loop conformations that expose the phosphatase substrate site, suggesting a strategy for improving kinase inhibitor potency and specificity.

• SB203580: From p38 Inhibition to Translation

  2026-09-16

  SB203580 offers a precise way to interrogate p38 MAPK activity while exposing the experimental decisions that determine translational value. This thought-leadership analysis connects ATP-site inhibition with the FAK–p38 MAPK–GATA4 axis implicated in diabetic bladder repair, and outlines a rigorous strategy for moving from pathway observation to causal evidence.

• SP600125: JNK Inhibition Beyond the Product Page

  2026-09-16

  SP600125 is more than a pathway inhibitor: it is a practical instrument for separating JNK-dependent transcription, cytokine output, and cell fate from the broader stress-response network. This thought-leadership guide connects biochemical selectivity with translational assay design, while defining what the current evidence supports—and what remains to be tested.

• Rotigotine Assay Design: From Receptor Biology to QC

  2026-09-15

  Rotigotine is a dopamine D2/D3 receptor agonist with a broader receptor profile than a simple pathway probe. This article provides a practical framework linking receptor pharmacology, model selection, assay controls, and impurity-aware analytical quality control.

• Neuroligin 1 Proteolysis Sustains Social Memory

  2026-09-15

  A 2025 study identifies activity-dependent Neuroligin 1 proteolysis in the ventral hippocampus as a mechanism that maintains, rather than merely forms, social memory. Its combination of secretase perturbation, domain-specific peptide rescue, behavioral testing, and synaptic readouts links NLG1-CTD signaling to cofilin regulation and dendritic spine remodeling.

• Anisomycin Workflows for JNK Apoptosis Research

  2026-09-14

  Build reproducible JNK activation and apoptosis assays with Anisomycin, from rapid phospho-signaling screens to delayed cell-death endpoints. The same workflow logic also helps position JNK perturbation alongside emerging synaptic-plasticity research without confusing pathway activation with proof of mechanism.

• Acetoacetic Acid Sodium Salt in Metabolic Assays

  2026-09-14

  Acetoacetic acid sodium salt is a practical model substrate for investigating ketone-body biology, fatty acid catabolism, and diabetes metabolic imbalance. This article connects chemical handling and assay interpretation with an isotope-labeling study to define stronger experimental decisions.

• Cell Cycle Assay Kit: Mechanistic DNA-Content Analysis

  2026-09-13

  Discover how the Cell Cycle Assay Kit (K2263) converts DNA content into mechanistic insight for cell cycle progression analysis, apoptosis detection, and cancer research. This guide connects PI/RNase A flow cytometry with recent findings on CGF-driven colorectal cancer stress and cell-cycle arrest.

• SB 202190: Practical p38 MAPK Workflow Guide

  2026-09-12

  Use SB 202190 as a cell-permeable p38 MAP kinase inhibitor to connect target engagement with cytokine, apoptosis, proliferation, and live-cell signaling readouts. This guide combines product-aligned dosing with single-cell ERK concepts from colorectal cancer organoid research, while emphasizing controls, timing, and troubleshooting.

• Imidazoline Antagonists and β-Cell K+ Channels

  2026-09-12

  This 1992 study showed that alinidine, antazoline, phentolamine, and tolazoline stimulate insulin release primarily by inhibiting ATP-sensitive K+ channels in pancreatic β-cells, rather than through α2-adrenoceptor antagonism alone. By combining 86Rb efflux, whole-cell patch clamp, and pharmacological rescue experiments, the authors established a useful framework for separating receptor-mediated effects from direct ion-channel actions.

• Reactive Astrocytes, p38 MAPK, and Neuroinflammation

  2026-09-11

  The reference study identifies 2-chloroethanol-activated A1 reactive astrocytes as an upstream driver of M1 microglial polarization in a model of 1,2-dichloroethane-associated neuroinflammation. Its main contribution is to define astrocyte-derived IL-1β and TNF-α as potential communication signals linking chemical stress, p38 MAPK-related transcriptional responses, and microglial inflammatory activation.

• JXY and TLR4-Driven Macrophage Polarization in CAC

  2026-09-11

  Liu et al. show that Jiedu Xiaozheng Yin suppresses colitis-associated colorectal cancer in mice while shifting intestinal macrophages toward an M1-like phenotype through TLR4-associated signaling. The study combines an orthotopic cancer model with macrophage assays, providing a mechanistic framework for interpreting immune modulation rather than treating tumor reduction as a direct cytotoxic effect.

• BMN 673 (Talazoparib) in DNA Repair Research

  2026-09-10

  BMN 673 (Talazoparib) combines exceptionally potent PARP1/2 inhibition with strong PARP-DNA complex trapping, making it useful for modeling DNA repair deficiency beyond conventional viability assays. This workflow connects homologous recombination status, spliceosome regulation, and combination-response profiling in HCC, SCLC, and other oncology models.

• Protease Inhibitor Cocktail: EDTA-Free 200X

  2026-09-10

  Protease Inhibitor Cocktail (EDTA-Free, 200X in DMSO) helps limit proteolytic loss during protein extraction and protease-sensitive assays without introducing EDTA into the workflow. It is suited to Western blotting, co-immunoprecipitation, pull-down, phosphorylation, and cation-sensitive enzyme workflows, but requires validation for cell-line sensitivity, DMSO tolerance, and protease classes not covered by the listed inhibitors.

8599 records 1/574 page Next 12345 下5页 Last page